Appili Therapeutics Raises an Additional $4.3 Million in Oversubscribed Financing to Advance its Anti-infective Pipeline

HALIFAX, Nova Scotia, February 7, 2018 – Appili Therapeutics Inc. (the “Company” or “Appili”), a biopharmaceutical company developing and commercializing anti-infective drugs, announced today it raised an additional $4,339,000 in an oversubscribed private placement financing, bringing the total equity raised since its seed round in March 2016 to $11,816,000. In addition, Appili is also pleased to be receiving a $500,000 repayable contribution from the Government of Canada, through the Atlantic Canada Opportunities Agency’s (ACOA) Business Development Program.

Details

Appili Recognized as ‘New Business of the Year’ by the Halifax Chamber of Commerce

HALIFAX, Nova Scotia, January 26, 2018 – Appili Therapeutics Inc. (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development and commercialization, today announced that Halifax Chamber of Commerce presented Appili with its 2018 ‘New Business of the Year’ award. The announcement was made during a ceremony at the Halifax Business Awards gala event on Thursday, January 25, 2018, held at the Halifax Convention Centre. Kevin Sullivan, Appili’s Chief Executive Officer, accepted the award on behalf of the Company.

Details

Appili Therapeutics Licenses BioTerrorism Vaccine Rights

HALIFAX, Nova Scotia, January 9, 2018 – Appili Therapeutics Inc. (the “Company” or “Appili”), an anti-infective drug development company, announced today it has signed a licence agreement with the National Research Council of Canada (NRC) to develop ATI-1701, a vaccine to protect against Francisella tularensis, a potential bioterrorism agent that causes tularemia.

Details

Appili Therapeutics Appoints Seasoned Biotech Executive Ian C. Mortimer to its Board

HALIFAX, Nova Scotia, November 28, 2017 – Appili Therapeutics Inc. (the “Company” or “Appili”), an anti-infective drug development company, is pleased to announce the appointment of Ian C. Mortimer to its Board of Directors. Mr. Mortimer is a seasoned biotechnology executive with proven abilities in leading capital market transactions. He will serve as chair of Appili’s audit committee.

Details

Appili Therapeutics Receives $1.2M USD from the Department of Defense to Advance Antibiotic Targeting Drug-Resistant Bacteria

November 7, 2017 – HALIFAX, Nova Scotia –– Appili Therapeutics Inc. (the “Company” or “Appili”), an anti-infective drug development company, announced today it has been awarded a $1.2 million USD grant by the Department of Defense, Congressionally Directed Medical Research Programs, Peer Reviewed Medical Research Program .

Details

Appili Receives FDA and Health Canada Clearance to Begin Clinical Trials of its Antibiotic Oral Liquid Reformulation

HALIFAX, Nova Scotia – October 30, 2017 – Appili Therapeutics Inc. (the “Company” or “Appili”), an anti-infective drug development company, announced today that both the US Food and Drug Administration (FDA) and Health Canada have cleared its IND and CTA clinical investigation applications, respectively, to conduct a clinical trial of ATI-1501, a taste-masked antibiotic targeting anaerobic bacteria like Clostridium difficile. ATI-1501 has been optimized in an oral liquid suspension to provide patients who have difficulty swallowing with a more convenient alternative to the currently marketed metronidazole tablet.

Details

Appili Therapeutics Inc. Appoints Pharmaceutical Executive Sean McBride as Vice President, Business Development

July 6, 2017 – HALIFAX, Nova Scotia –– Appili Therapeutics Inc. (“Appili”), an anti-infective drug development company, announced today that Sean McBride, a 26 year pharmaceutical veteran, has joined the company as Vice President, Business Development. Mr. McBride will lead Appili’s out-licensing, product in-licensing and acquisition opportunities as the company builds its pipeline of infectious disease products.

Details